Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient
Gespeichert in:
| Veröffentlicht in: | Seizure (London, England) England), 2020-08, Vol.80, p.157-158 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 158 |
|---|---|
| container_issue | |
| container_start_page | 157 |
| container_title | Seizure (London, England) |
| container_volume | 80 |
| creator | Gómez-Enjuto, Sara Hernando-Requejo, Virgilio Lapeña-Motilva, José Ogando-Durán, Gonzalo Fouz-Ruiz, Daniel Domingo-García, Julio Rodríguez-García, Elena Cemillán-Fernández, Carlos Alberto |
| description | |
| doi_str_mv | 10.1016/j.seizure.2020.06.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7275169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1059131120301709</els_id><sourcerecordid>2416943936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-8a2c6cf4aded9087d2f1898a1102be6ed4aa925e4ab4a3a20287d2727ac087fa3</originalsourceid><addsrcrecordid>eNqFkU1vFDEMhiNERT_gJ4By5DJDkvm-gKpVS5EqFXWBa-RNPJDVzGRIMiuVX49Xu1TtiZMt-fFr630ZeytFLoWsP2zziO7PEjBXQolc1LkQ7Qt2JqtCZapu25fUi6rLZCHlKTuPcSuE6EpZvGKnhaqasi3aM5Z-YIAZRjdwiDwFhDTilHjvAw_YBzDJhwceE6QlcpzdgHNyhvqIxk8WaJg8_3p_tebxYbLBj8j9xIGvL-_X2crvMsXd1KNJaPkMyZH6a3bSwxDxzbFesO_XV99WN9nt3ecvq8vbzJR1k7IWlKlNX4JF24m2saqXbdeClEJtsEZbAnSqwhI2JRRAPuyZRjVgiO6huGAfD7rzshnRGjodYNBzcCP9rT04_XwyuV_6p99p0qhk3ZHA-6NA8L8XjEmPLhocBpjQL1Grkqiy6Iqa0OqAmuBjJOsez0ih94nprT4mpveJaVFrSoz23j398XHrX0QEfDoASE7tHAYdDZlo0LpArmrr3X9O_AXFA62L</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2416943936</pqid></control><display><type>article</type><title>Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gómez-Enjuto, Sara ; Hernando-Requejo, Virgilio ; Lapeña-Motilva, José ; Ogando-Durán, Gonzalo ; Fouz-Ruiz, Daniel ; Domingo-García, Julio ; Rodríguez-García, Elena ; Cemillán-Fernández, Carlos Alberto</creator><creatorcontrib>Gómez-Enjuto, Sara ; Hernando-Requejo, Virgilio ; Lapeña-Motilva, José ; Ogando-Durán, Gonzalo ; Fouz-Ruiz, Daniel ; Domingo-García, Julio ; Rodríguez-García, Elena ; Cemillán-Fernández, Carlos Alberto</creatorcontrib><identifier>ISSN: 1059-1311</identifier><identifier>EISSN: 1532-2688</identifier><identifier>DOI: 10.1016/j.seizure.2020.06.008</identifier><identifier>PMID: 32574838</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Anemia - etiology ; Anticoagulants - therapeutic use ; Anticonvulsants - therapeutic use ; Antiviral Agents - therapeutic use ; Betacoronavirus ; Calcium Channel Blockers - therapeutic use ; Coronavirus Infections - complications ; Coronavirus Infections - drug therapy ; Coronavirus Infections - physiopathology ; COVID-19 ; Drug Combinations ; Enzyme Inhibitors - therapeutic use ; Humans ; Hydroxychloroquine - therapeutic use ; Lopinavir - therapeutic use ; Lymphopenia - etiology ; Male ; Pandemics ; Pneumonia, Viral - complications ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - physiopathology ; Posterior Leukoencephalopathy Syndrome - diagnostic imaging ; Posterior Leukoencephalopathy Syndrome - etiology ; Posterior Leukoencephalopathy Syndrome - physiopathology ; PRES ; Ritonavir - therapeutic use ; SARS-CoV-2 ; Status epilepticus ; Status Epilepticus - drug therapy ; Status Epilepticus - etiology ; Verapamil ; Verapamil - therapeutic use</subject><ispartof>Seizure (London, England), 2020-08, Vol.80, p.157-158</ispartof><rights>2020 British Epilepsy Association</rights><rights>2020 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. 2020 British Epilepsy Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-8a2c6cf4aded9087d2f1898a1102be6ed4aa925e4ab4a3a20287d2727ac087fa3</citedby><cites>FETCH-LOGICAL-c467t-8a2c6cf4aded9087d2f1898a1102be6ed4aa925e4ab4a3a20287d2727ac087fa3</cites><orcidid>0000-0003-3247-4246</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1059131120301709$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32574838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez-Enjuto, Sara</creatorcontrib><creatorcontrib>Hernando-Requejo, Virgilio</creatorcontrib><creatorcontrib>Lapeña-Motilva, José</creatorcontrib><creatorcontrib>Ogando-Durán, Gonzalo</creatorcontrib><creatorcontrib>Fouz-Ruiz, Daniel</creatorcontrib><creatorcontrib>Domingo-García, Julio</creatorcontrib><creatorcontrib>Rodríguez-García, Elena</creatorcontrib><creatorcontrib>Cemillán-Fernández, Carlos Alberto</creatorcontrib><title>Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient</title><title>Seizure (London, England)</title><addtitle>Seizure</addtitle><subject>Aged</subject><subject>Anemia - etiology</subject><subject>Anticoagulants - therapeutic use</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Betacoronavirus</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Coronavirus Infections - complications</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - physiopathology</subject><subject>COVID-19</subject><subject>Drug Combinations</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>Lopinavir - therapeutic use</subject><subject>Lymphopenia - etiology</subject><subject>Male</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - complications</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - physiopathology</subject><subject>Posterior Leukoencephalopathy Syndrome - diagnostic imaging</subject><subject>Posterior Leukoencephalopathy Syndrome - etiology</subject><subject>Posterior Leukoencephalopathy Syndrome - physiopathology</subject><subject>PRES</subject><subject>Ritonavir - therapeutic use</subject><subject>SARS-CoV-2</subject><subject>Status epilepticus</subject><subject>Status Epilepticus - drug therapy</subject><subject>Status Epilepticus - etiology</subject><subject>Verapamil</subject><subject>Verapamil - therapeutic use</subject><issn>1059-1311</issn><issn>1532-2688</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1vFDEMhiNERT_gJ4By5DJDkvm-gKpVS5EqFXWBa-RNPJDVzGRIMiuVX49Xu1TtiZMt-fFr630ZeytFLoWsP2zziO7PEjBXQolc1LkQ7Qt2JqtCZapu25fUi6rLZCHlKTuPcSuE6EpZvGKnhaqasi3aM5Z-YIAZRjdwiDwFhDTilHjvAw_YBzDJhwceE6QlcpzdgHNyhvqIxk8WaJg8_3p_tebxYbLBj8j9xIGvL-_X2crvMsXd1KNJaPkMyZH6a3bSwxDxzbFesO_XV99WN9nt3ecvq8vbzJR1k7IWlKlNX4JF24m2saqXbdeClEJtsEZbAnSqwhI2JRRAPuyZRjVgiO6huGAfD7rzshnRGjodYNBzcCP9rT04_XwyuV_6p99p0qhk3ZHA-6NA8L8XjEmPLhocBpjQL1Grkqiy6Iqa0OqAmuBjJOsez0ih94nprT4mpveJaVFrSoz23j398XHrX0QEfDoASE7tHAYdDZlo0LpArmrr3X9O_AXFA62L</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Gómez-Enjuto, Sara</creator><creator>Hernando-Requejo, Virgilio</creator><creator>Lapeña-Motilva, José</creator><creator>Ogando-Durán, Gonzalo</creator><creator>Fouz-Ruiz, Daniel</creator><creator>Domingo-García, Julio</creator><creator>Rodríguez-García, Elena</creator><creator>Cemillán-Fernández, Carlos Alberto</creator><general>Elsevier Ltd</general><general>British Epilepsy Association. Published by Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3247-4246</orcidid></search><sort><creationdate>20200801</creationdate><title>Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient</title><author>Gómez-Enjuto, Sara ; Hernando-Requejo, Virgilio ; Lapeña-Motilva, José ; Ogando-Durán, Gonzalo ; Fouz-Ruiz, Daniel ; Domingo-García, Julio ; Rodríguez-García, Elena ; Cemillán-Fernández, Carlos Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-8a2c6cf4aded9087d2f1898a1102be6ed4aa925e4ab4a3a20287d2727ac087fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Anemia - etiology</topic><topic>Anticoagulants - therapeutic use</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Betacoronavirus</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Coronavirus Infections - complications</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - physiopathology</topic><topic>COVID-19</topic><topic>Drug Combinations</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>Lopinavir - therapeutic use</topic><topic>Lymphopenia - etiology</topic><topic>Male</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - complications</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - physiopathology</topic><topic>Posterior Leukoencephalopathy Syndrome - diagnostic imaging</topic><topic>Posterior Leukoencephalopathy Syndrome - etiology</topic><topic>Posterior Leukoencephalopathy Syndrome - physiopathology</topic><topic>PRES</topic><topic>Ritonavir - therapeutic use</topic><topic>SARS-CoV-2</topic><topic>Status epilepticus</topic><topic>Status Epilepticus - drug therapy</topic><topic>Status Epilepticus - etiology</topic><topic>Verapamil</topic><topic>Verapamil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez-Enjuto, Sara</creatorcontrib><creatorcontrib>Hernando-Requejo, Virgilio</creatorcontrib><creatorcontrib>Lapeña-Motilva, José</creatorcontrib><creatorcontrib>Ogando-Durán, Gonzalo</creatorcontrib><creatorcontrib>Fouz-Ruiz, Daniel</creatorcontrib><creatorcontrib>Domingo-García, Julio</creatorcontrib><creatorcontrib>Rodríguez-García, Elena</creatorcontrib><creatorcontrib>Cemillán-Fernández, Carlos Alberto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Seizure (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez-Enjuto, Sara</au><au>Hernando-Requejo, Virgilio</au><au>Lapeña-Motilva, José</au><au>Ogando-Durán, Gonzalo</au><au>Fouz-Ruiz, Daniel</au><au>Domingo-García, Julio</au><au>Rodríguez-García, Elena</au><au>Cemillán-Fernández, Carlos Alberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient</atitle><jtitle>Seizure (London, England)</jtitle><addtitle>Seizure</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>80</volume><spage>157</spage><epage>158</epage><pages>157-158</pages><issn>1059-1311</issn><eissn>1532-2688</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32574838</pmid><doi>10.1016/j.seizure.2020.06.008</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0003-3247-4246</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1059-1311 |
| ispartof | Seizure (London, England), 2020-08, Vol.80, p.157-158 |
| issn | 1059-1311 1532-2688 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7275169 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Aged Anemia - etiology Anticoagulants - therapeutic use Anticonvulsants - therapeutic use Antiviral Agents - therapeutic use Betacoronavirus Calcium Channel Blockers - therapeutic use Coronavirus Infections - complications Coronavirus Infections - drug therapy Coronavirus Infections - physiopathology COVID-19 Drug Combinations Enzyme Inhibitors - therapeutic use Humans Hydroxychloroquine - therapeutic use Lopinavir - therapeutic use Lymphopenia - etiology Male Pandemics Pneumonia, Viral - complications Pneumonia, Viral - drug therapy Pneumonia, Viral - physiopathology Posterior Leukoencephalopathy Syndrome - diagnostic imaging Posterior Leukoencephalopathy Syndrome - etiology Posterior Leukoencephalopathy Syndrome - physiopathology PRES Ritonavir - therapeutic use SARS-CoV-2 Status epilepticus Status Epilepticus - drug therapy Status Epilepticus - etiology Verapamil Verapamil - therapeutic use |
| title | Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T13%3A00%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Verapamil%20as%20treatment%20for%20refractory%20status%20epilepticus%20secondary%20to%20PRES%20syndrome%20on%20a%20SARS-Cov-2%20infected%20patient&rft.jtitle=Seizure%20(London,%20England)&rft.au=G%C3%B3mez-Enjuto,%20Sara&rft.date=2020-08-01&rft.volume=80&rft.spage=157&rft.epage=158&rft.pages=157-158&rft.issn=1059-1311&rft.eissn=1532-2688&rft_id=info:doi/10.1016/j.seizure.2020.06.008&rft_dat=%3Cproquest_pubme%3E2416943936%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2416943936&rft_id=info:pmid/32574838&rft_els_id=S1059131120301709&rfr_iscdi=true |